Skip to content

Effect of remimazolam on autonomic circulatory control function

Effect of remimazolam on autonomic circulatory control function: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1031240189
Enrollment
40
Registered
2024-06-27
Start date
2024-07-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diseases that require general anesthesia in the operating room

Interventions

Assign anesthesia maintenance to propofol group and remimazolam group. In the propofol group, propofol 2-2.5 mg/kg was administered intravenously, and in the remimazolam group, remimazolam 12 mg/kg/ho

Sponsors

Sato Hanae
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Persons who are between 18 and 65 years old at the time of obtaining consent (pre-operative examination) 2) Cases with American Society of Anesthesiologists pre-anesthesia risk assessment 2 or lower (ASA classification 1: No organic, physiological, biochemical or mental abnormality. 2: Mild to moderate systematic disorder. 3: Severe systematic disorder. 4: Severe systematic disease that is threatening life and cannot be cured even with surgery.) 3) Subjects who have received sufficient explanation at the pre-operative examination to participate in this study, and who have given their voluntary written informed consent with full understanding.

Exclusion criteria

Exclusion criteria: 1)Patients with autonomic nerve imbalance 2)Patients with hypertension 3) Cases with moderate to severe systemic complications (American Society of Anesthesiologists preanesthesia risk assessment 3 or higher) 4)Poorly controlled diabetic patients 5) Patients taking oral medications that affect the autonomic nervous system 6)Other persons who are judged by the research director to be inappropriate as research subjects. 7) Persons who have requested refusal to participate in this research

Design outcomes

Primary

MeasureTime frame
Spontaneous fluctuation waveforms of heart rate and blood pressure obtained from electrocardiogram and arterial pressure waveforms

Secondary

MeasureTime frame
Heart rate, blood pressure, cardiac output, respiratory rate, end-tidal carbon dioxide concentration, percutaneous arterial oxygen saturation, BIS value

Contacts

Public ContactHanae Sato

Nihon University School of Medicine

nakamura.hanae@nihon-u.ac.jp+81-3-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026